Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hui Sheng insulin degludec versus Tresiba in Chinese adults with type 2 diabetes
ChiCTR2400081763Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin degludec in type 2 diabetes mellitus (T2DM), sponsored by Peking University People's Hospital. Primary endpoint: Change from baseline in HbA1c. Started Mar 2024; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400081763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081763.